PeproMene Bio Reports Results from the P-I Study of PMB-CT01 for the Treatment of R/R B-Cell Acute Lymphoblastic Leukemia
Shots:
- The first patient in cohort 1 treated with PMB-CT01 (BAFFR-CAR T Cells) achieved complete remission 1mos. post-treatment in the P-I study for r/r B-cell acute lymphoblastic leukemia (r/r B-ALL)
- In the initial month of treatment, the patients observed low-grade treatment-related side effects, such as grade 1 cytokine release syndrome that resolved without intervention and no instances of immune effector cell-associated neurotoxicity syndrome were reported
- PMB-CT01 is an autologous CAR-T cell therapy that targets BAFFR (B Cell Activating Factor Receptor), a tumor necrosis factor (TNF) receptor, primarily expressed in B cells
Ref: PRNewswire | Image: PeproMene Bio
Related News:- Jazz’ Enrylaze Receives EC’s Approval for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.co
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
